Spravato/Esketamine

You may have heard about Spravato, also known as esketamine, after the FDA approved it for depression treatment in March 2019. You may have also heard of Spravato after the US Department of Veterans Affairs elected to offer the nasal spray to veterans needing treatment.

Spravato is an innovative new treatment that may bring relief to thousands suffering from previously treatment-resistant depression.

What is Spravato?

At Revitalist, clients receive Spravato nasal spray, a non-competitive N-methyl D-aspartate
(NDA) receptor antagonist indicated, in conjunction with an oral antidepressant, for the
treatment of treatment-resistant depression (TRD) in adults and depressive symptoms in adults
with major depressive disorder (MDD) with acute suicidal ideation or behavior.

What is Treatment-Resistant Depression (TRD)?

TRD is a form of depression that does not get better with traditional medication or therapy. It may improve symptoms for a short period of time, but they often come back quickly and can even be worse than before. TRD can require a new treatment option, such as Spravato (esketamine). Symptoms of TRD commonly include:

Why Choose Spravato at Revitalist?

Most insurance providers cover it
Provides rapid relief, sometimes within minutes
Brings a low risk of adverse side effects
Relieves previously treatment-resistant depression
Quick, convenient, and accessible treatment

In clinical trials, after 16 weeks of therapy, patients who stayed on Spravato were less likely to experience a return of depressive symptoms than those who stopped therapy. It is mandatory to have a direct referral from a mental health provider before being considered for treatment with Spravato. Once a referral is received, it is then necessary to schedule a consultation with a provider at Revitalist. Patients must enroll in the Spravato REMS to receive Spravato treatment.

Spravato Enrollment Information Requirements

After speaking with your mental health prescriber and agreeing this may be the best option for you and your condition, please visit SpravatoREMS.com and click “Patient Enrollment.” Please review “Spravato Medication Guide” and “Spravato Instructions For Use” found at the bottom of the page.

It is mandatory to have a direct referral from a mental health provider before being considered for treatment with Spravato. Your mental health provider may call (865) 290-2465 to refer you directly, or they may visit our site and click “Ketamine” and then “Provider” to fill out a referral form.

Once a referral is received, it is then necessary to schedule a consultation with a provider at Revitalist. This will be a comprehensive consultation that will include completing the Patient Enrollment Form (if all criteria for candidacy are met).

*Patients must be enrolled in the SPRAVATO™ REMS to receive SPRAVATO™ treatment.*

For additional information, visit https://www.spravatorems.com/patients.